Description: Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
Home Page: www.rvlpharma.com
RVLP Technical Analysis
400 Crossing Boulevard
Bridgewater,
NJ
08807
United States
Phone:
908 809 1300
Officers
| Name | Title |
|---|---|
| Mr. Brian A. Markison | Chairman, Pres, CEO & Principal Financial Officer |
| Mr. James D. Schaub | Exec. VP & COO |
| Mr. Christopher A. Klein | Gen. Counsel & Sec. |
| Mr. Michael J. DePetris | Principal Accounting Officer |
| Mr. Jarret Miller | Exec. VP of HR |
| Dr. Tina Marie deVries Ph.D. | Exec. VP of R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9383 |
| Price-to-Sales TTM: | 2.9208 |
| IPO Date: | 2018-10-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 156 |